Search Videos and More
Symposium
2022 ASCO Highlights
Review highlights of key advances in cancer research and an overview of Dana-Farber faculty presentations.
News
Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
Video
Marla Lipsyc-Sharf, MD on ctDNA in Breast Cancer
Using ctDNA found with liquid biopsy to understand recurrence risk in hormone receptor-positive breast cancer: Dana-Farber's Marla Lipsyc-Sharf MD, details research presented at #ASCO22 and published in the Journal of Clinical Oncology.
News
Improved Progression-Free Survival in Patients with Multiple Myeloma Following Three-Drug Therapy with Autologous Stem Cell Transplant
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
News
Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Video
Young-Onset Colorectal Cancer Center Gut Instincts Series: Best Practices for Symptom Management
Dana-Farber’s Young-Onset Colorectal Cancer Center's Gut Instincts series continued on Tuesday, January 25 with an educational workshop on Best Practices for Symptom Management.
Symposium
Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management
This course addresses the rapidly changing landscape in the management and treatment of non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
News
Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma
Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Video
cHL and CLL SLL Panel Discussion and Conclusion
In this video, the panel takes audience questions and discusses cases of Classical Hodgkin Lymphoma, Chronic Lymphocutic Leukemia, and Small Lymphocytic Lymphoma.
Video
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Inhye Ahn, MD, discusses the background and management of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Video
Hodgkin Lymphoma
Ann LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.
Video
CAR-T Cell Therapy for Lymphoma: Updates and Progress
Caron Jacobson, MD, MMSc, gives updates and shares progress with CAR-T cell therapy for lymphoma.